Key | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Royal Dutch Shell B | 4.3% |
BP | 4.2% |
Other | 82.4% |
Name | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Royal Dutch Shell B | 4.3% |
BP | 4.2% |
Vodafone Group | 4.2% |
British American Tobacco | 3.4% |
Aberforth UK Small Companies | 3.2% |
HSBC Holdings PLC (UK Reg) | 2.9% |
BG Group | 2.3% |
AstraZeneca | 2.3% |
No asset data available.
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 31/07/1998 |
---|---|
Fund Manager | n/a |
TER | - |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research